498 related articles for article (PubMed ID: 23406773)
21. New Concepts of Treatment for Patients with Myelofibrosis.
Bose P; Alfayez M; Verstovsek S
Curr Treat Options Oncol; 2019 Jan; 20(1):5. PubMed ID: 30675650
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate Is a JAK/STAT Pathway Inhibitor.
Thomas S; Fisher KH; Snowden JA; Danson SJ; Brown S; Zeidler MP
PLoS One; 2015; 10(7):e0130078. PubMed ID: 26131691
[TBL] [Abstract][Full Text] [Related]
23. Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors.
Álvarez-Reguera C; Prieto-Peña D; Herrero-Morant A; Sánchez-Bilbao L; Batlle-López A; Fernández-Luis S; Paz-Gandiaga N; Blanco R
Eur J Intern Med; 2024 May; 123():102-106. PubMed ID: 38044168
[TBL] [Abstract][Full Text] [Related]
24. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
Mesa RA
IDrugs; 2010 Jun; 13(6):394-403. PubMed ID: 20506062
[TBL] [Abstract][Full Text] [Related]
25. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
26. New JAK2 inhibitors for myeloproliferative neoplasms.
Quintás-Cardama A; Verstovsek S
Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
[TBL] [Abstract][Full Text] [Related]
27. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Smith JE; Peth K; Abhyankar S; McGuirk J; Bhalla KN
Mol Cancer Ther; 2013 May; 12(5):577-88. PubMed ID: 23445613
[TBL] [Abstract][Full Text] [Related]
28. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B; Biray Avci C
Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
[TBL] [Abstract][Full Text] [Related]
29. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Tyner JW; Bumm TG; Deininger J; Wood L; Aichberger KJ; Loriaux MM; Druker BJ; Burns CJ; Fantino E; Deininger MW
Blood; 2010 Jun; 115(25):5232-40. PubMed ID: 20385788
[TBL] [Abstract][Full Text] [Related]
30. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms.
Greenfield G; McPherson S; Mills K; McMullin MF
J Transl Med; 2018 Dec; 16(1):360. PubMed ID: 30558676
[TBL] [Abstract][Full Text] [Related]
31. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Oh ST; Simonds EF; Jones C; Hale MB; Goltsev Y; Gibbs KD; Merker JD; Zehnder JL; Nolan GP; Gotlib J
Blood; 2010 Aug; 116(6):988-92. PubMed ID: 20404132
[TBL] [Abstract][Full Text] [Related]
32. The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.
Keohane C; Mesa R; Harrison C
Am Soc Clin Oncol Educ Book; 2013; ():301-5. PubMed ID: 23714529
[TBL] [Abstract][Full Text] [Related]
33. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P; Verstovsek S
Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
[TBL] [Abstract][Full Text] [Related]
34. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
[TBL] [Abstract][Full Text] [Related]
35. Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies.
Scott LM; Gandhi MK
Blood Rev; 2015 Nov; 29(6):405-15. PubMed ID: 26123794
[TBL] [Abstract][Full Text] [Related]
36. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
38. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
39. A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.
Gorantla SP; Mueller TA; Albers-Leischner C; Rudelius M; von Bubnoff N; Duyster J
Mol Oncol; 2024 Feb; 18(2):415-430. PubMed ID: 38104968
[TBL] [Abstract][Full Text] [Related]
40. JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside.
Gotlib J
Hematology Am Soc Hematol Educ Program; 2013; 2013():529-37. PubMed ID: 24319228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]